About HRPP Contact Us Consent Assistant Dates Fact Sheets e-IRB Services Forms Guidelines Links News Public Notices Research Directory School of Medicine Training UCSD InfoPath		As a reminder, please ensure that complete continuing review materials are submitted approximately 45 days prior to expiration (check the most recent approval letter) to avoid any lapse in approval or the need to submit a NEW application should the study's approval expire. Also, if there is no lapse in approval, a study may receive up to 4 IRB reviews. A study may undergo an Initial and 3 Continuing Reviews. Please check the status of the study carefully before submitting Continuing Review materials. Updated Form and Fact Sheet. The form, Continuing Review Narrative Summary of Progress to Date, has been updated to include an additional section to report adverse events (non-URPs) at this site to the IRB. This updated form can be found here. In addition, the fact sheet, Submitting an Amendment/Modification to a Research Plan (Protocol), has been updated including a more specfic description of information required in association with an amendment request. The updated fact sheet can be found here. (Released 1/26/09) SDSU/UCSD Agreement for Joint Doctoral Program Research Review. The students enrolled in a SDSU/UCSD Joint Doctoral Program (JDP) who plan to involve human subjects in research are required to obtain approval from both the SDSU and UCSD Institutional Review Boards in advance of initiating research. We are pleased to announce that an agreement between SDSU and UCSD is now in place allowing for a cooperative review of research protocols involving SDSU/UCSD JDP students. Under this agreement, one campus will serve as the "reviewing" IRB and the other as the "relying" IRB. More information about this agreement and application submitting procedures can be found here. (Released 9/19/08) Pre-screening of all "new" applications. As of September 24, 2008, the HRPP will be pre-screening all new applications submitted for review. This pre-screening is designed to comply with federal rules by ensuring the documentation necessary for an accurate and thorough review of the application is obtained prior to the IRB review. As noted in a prior announcement, incomplete applications will not be placed on an IRB meeting agenda. HRPP staff will notify PIs of incomplete submissions and provide information regarding missing documentation. When an application is found to be complete, it will be assigned to the next appropriate IRB meeting. It is important to note that incomplete applications cannot attain final approval by the IRB. A copy of the IRB pre-screening form can be found here. (Released 9/19/08) HRPP announces new guidelines for reporting adverse events to the IRB. Investigators often engage in a popular strategy of over-reporting and relying in the IRB triage mechanisms for deciding what reports go to convened meetings. OHRP notes that because most individual adverse events (AEs) do not appear to represent unanticipated problems, the vast majority of AEs do not need to be reported to the IRB. UCSD's HRPP has revised its Standard Operating Policies and Procedures in response to recent guidance provided by OHRP, the FDA and the VA Office of Research Oversight. Guidance for Prinicipal Investigators and research staff when reporting unanticipated problems or adverse events to the IRB is provided in this fact sheet. VA Privacy and Data Security Plan. VA investigators are now required to include procedures in their Research Plans for ensuring safety and security of VA research data. Guidelines and recommendations for this VA requirement can be found here. Hybrid Consent Information Update. The VA R&D review process is currently undergoing a transition and that office has contacted researchers directly. As a result of the changes in process, studies including both UCSD and VA sites and/or investigators may be affected. Therefore, during this period, it has been determined that it may be best for researchers to continue to submit separate UCSD and VA/VMRF consents rather than use the newly proposed VA hybrid consent when submitting NEW applications for IRB review. In addition, institutional contractual agreements (such as clinical trial agreements or CTAs) may differ between institutions that can impact consent language. A review by these offices of the proposed hybrid consent is underway. Please note: should you already have an approved hybrid consent, continued use is acceptable at this time through the expiration period until further notice. Change in fee schedule for commercially sponsored clincial trials. As of September 1, 2008, there will be a change in the fee for IRB review of commercially sponsored clinical trials to reflect a flat rate of $1600 for an initial review and $1600 for each 4-year "re-submission" (treated as a "new" project by the IRB) review and $400 for each annual continuing review. For more information about this, please see the HRPP fact sheet "Institutional Review Board (IRB) fees for commercially sponsored projects" located here. Beginning June 15, 2008--New Requirements for VA Human Studies. VA investigators have been notified by the ACOS R&D (memo dated 5/28/08) that in order to ensure that all VA-related research projects undergo R&D Committee review, the R&D Committee has required that an R&D application be initiated prior to IRB review and that a receipt of that application accompany the IRB application. A fact sheet detailing this requirement and outling the "VA Receipt of Review Request" form is available here. The VA has stated that this may appear to create additional burdens in the application and approval process for studies; however, the intent is to coordinate reviews by both the IRB and the R&D Committee and to allow processes to proceed in parallel where possible. Pediatric IRB Information. The Pediatric IRB "D" Committee was launched in May 2007. As announced, IRB submissions involving children and adolescents will be assigned to this Committee because of expertise. As the "D" Committee only meets once per month, please ensure careful review of due dates and meeting dates to avoid significant delay or any lapse in approval. (In general, no research may be conducted if a protocol has been allowed to expire.) The meeting due dates can be found here. Senate Bill 13 requires that the Health and Human Services Agency's Committee for the Protection of Human Subjects approve scientific research proposals before state agencies are permitted to disclose personal information to researchers. If the proposed research involves this type of data, this fact sheet provides background information. The Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) has provided new guidance to Institutional Review Boards for the review of information provided to potential research subjects through clinical trial websites. This guidance describes the circumstances for which IRB review of clinical trial websites is both required and not required. Websites, along with print and broadcast advertisements, are commonly used by investigators and institutions to recruit research subjects. Details here... The International Committee of Medical Journal Editors (ICMJE) that represents major journals now requires that clinical trials be registered in a publicly accessible trials' registry. Details here... Effective January 1, 2005, the maximum project lifespan for IRB study numbers (protocol numbers) will be up to four review periods rather than two.  Federal regulations require Continuing Review by the IRB at intervals that will avoid lapses in approval and are not more than than 365 days post initial/continuing review approval. An online Continuing Review submission process is available via the e-IRB My Protocols at a Glance service.  Should you not have access to that e-IRB, the fillable forms are also available at http://irb.ucsd.edu/forms.shtml. Projects extending beyond the initial review period (up to 365 days) will be eligible for up to three cycles of Continuing Review.  (November 28, 2004) Revised Guidelines for Studies involving Placebo in High Risk Patients with Psychiatric Illnesses (November 4, 2004) Single Submission/Dual Tracking by UCSD and San Diego Childrens Hospital and Health Center IRBs now available for investigators doing pediatric research, (6/1/2004) Public Notice of UCSD researchers' plans to test a blood substitute for treatment of life-threatening injury.  Details here... (7/23/03) HIPAA (Health Insurance Portability and Accountability Act of 1996) requirements for research become effective April 14, 2003. Details here... New California law on use of State Death Records for Research effective January 1, 2003, requires IRB review of projects that will use decedent records. (1/27/2003) New procedures  for Surrogate Consent became law in California, and will affect any project that uses a "Legally Authorized Representative" signature line in its informed consent documents. (1/10/2003)  More... Final Guidelines for determining Decision-Making Capacity of study participants have been developed by a UCSD Task Force. Decisional Making Capacity assessment will be a component of many projects that employ Surrogate Consent. See details here.  (1/10/2003) An "almost paperless" online project submission and review, the "e-IRB" for new project submissions, is now available. (6/11/2002)